Clinical trials
NMIBC clinical trials
Below are recruiting nmibc clinical trials, each written for real people, not researchers. We’re tracking 44 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07725796RecruitingPhase 1
Study of UGN-501 for recurrent bladder cancer
This study tests an experimental medicine called UGN-501 given directly into the bladder. It is for people whose bladder cancer has come back despite previous treatments, such as BCG therapy. The goal is to find the best dose and see how safe and effective it is.
Queen Creek, ArizonaAges 18 years+ - NCT07322263RecruitingPhase 2
Gemcitabine and docetaxel for bladder cancer that returned after BCG
This trial tests a combination of two chemotherapy drugs (gemcitabine and docetaxel) given directly into the bladder to treat high-risk non-muscle-invasive bladder cancer that has come back or not responded to BCG therapy. It's for people who cannot or choose not to have their bladder removed.
Iowa City, IowaAges 18–99 - NCT06800963RecruitingPhase 1/Phase 2
A new BCG treatment for bladder cancer that hasn't spread
This trial tests a new form of intravesical (given directly into the bladder) treatment called rMBCG for people with non-muscle invasive bladder cancer who have not had BCG therapy before. It may be an option for those with certain types of early bladder cancer, including carcinoma in situ (CIS) or papillary tumors after removal surgery.
Chandler, ArizonaAges 18–85 - NCT05943379RecruitingPhase 2
RC48 antibody plus gemcitabine for high-risk bladder cancer
This Phase 2 study tests RC48, an antibody-based drug, combined with gemcitabine to treat high-risk, non-muscle invasive bladder cancer that has not responded well to BCG or cannot receive BCG. It may help shrink tumors and reduce the chance of the cancer coming back.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07763197Recruiting
Sample collection for bladder cancer research
This study is collecting blood, urine, and tissue samples from people with high-risk non-muscle invasive bladder cancer to help develop better tests for tracking the disease. By participating, you might help improve future monitoring and treatment decisions.
Austin, TexasAges 18 years+ - NCT07749924Recruiting
Watchful waiting vs. bladder chemotherapy for intermediate-risk bladder cancer
This study compares two approaches for people with intermediate-risk bladder cancer whose urine shows no signs of cancer after surgery. One group will be watched closely (active surveillance), while the other will receive chemotherapy directly into the bladder (intravesical chemotherapy). The goal is to see if surveillance alone can prevent unnecessary treatment while keeping the cancer controlled.
DaqingAges 18 years+ - NCT06186414RecruitingPhase 1
SIM0237 with or without BCG for bladder cancer
This trial tests a new drug, SIM0237, alone or with BCG, for people with a type of bladder cancer called non-muscle invasive bladder cancer (NMIBC) that did not respond to BCG treatment. The goal is to see if it is safe and works against the cancer.
Beijing, Beijing MunicipalityAges 18 years+ - NCT05410730RecruitingPhase 1/Phase 2
Early bladder cancer study using new drugs and BCG
This trial tests whether a new bladder cancer drug (SHR-1501) works alone or combined with BCG, and compares options with another drug (SHR-1316), in people with high-risk non–muscle-invasive bladder cancer. It may help reduce cancer coming back and improve control of the disease.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07424287RecruitingPhase 3
New drug plus BCG vs chemo for BCG-resistant bladder cancer
This trial tests a new combination treatment (SHR-1501 plus BCG) compared to standard chemotherapy for people with bladder cancer that hasn't responded to BCG. The goal is to see if this combination works better at controlling the cancer.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06696794RecruitingPhase 3
Testing mitomycin before surgery for high-risk bladder cancer
This trial tests whether giving mitomycin directly into the bladder before surgery can help people with high-risk non-muscle-invasive bladder cancer. The goal is to see if this approach is safe and effective at preventing cancer from coming back.
Wuhan, HubeiAges 18–75 - NCT07207824RecruitingPhase 3
Study of a new drug for high-risk bladder cancer
This trial tests a combination of a drug (DV) and BCG immunotherapy for people with high-risk, early-stage bladder cancer that has not spread into the muscle. The cancer must show a specific protein called HER2 on its cells.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06971614RecruitingPhase 2
T3011 for bladder cancer not responding to standard treatments
This trial tests a drug called T3011 for a type of bladder cancer that hasn't responded to standard treatments like BCG or chemotherapy. It aims to see if T3011 can help shrink the cancer or keep it from growing, offering a new option for people who have limited choices.
Queen Creek, ArizonaAges 18 years+ - NCT06351904RecruitingPhase 1
Testing RAG-01 for bladder cancer that returned after BCG treatment
This trial tests a new drug, RAG-01, for people with a type of bladder cancer called non-muscle-invasive bladder cancer (NMIBC) that has come back after BCG therapy. The drug is given through a catheter into the bladder, and the study aims to see if it can help control the cancer.
St Leonards, New South WalesAges 18–75 - NCT03945162RecruitingPhase 2
Bladder cancer trial using light therapy in the bladder
This Phase 2 study tests a treatment called photodynamic therapy (PDT) placed directly into the bladder. It may help people whose non–muscle-invasive bladder cancer did not respond to BCG treatment or could not tolerate it.
Chicago, IllinoisAges 18 years+ - NCT04752722RecruitingPhase 1/Phase 2
Gene therapy for bladder cancer that came back after BCG
This study tests a new gene therapy (EG-70) given directly into the bladder for people with a high-risk bladder cancer called NMIBC. It may be an option if BCG treatment stopped working, or if you cannot have or choose not to have bladder removal surgery.
Birmingham, AlabamaAges 18 years+ - NCT07625527RecruitingPhase 2
Stopping immunotherapy after bladder cancer disappears
This trial tests whether it's safe to stop immunotherapy once bladder cancer is no longer visible, instead of continuing it for a longer time. It aims to find out if stopping treatment early can reduce side effects while keeping the cancer from coming back.
TianjinAges 18 years+ - NCT07860398Recruiting
Laser distance control for bladder tumor treatment
This trial tests a new laser system that automatically controls distance during outpatient treatment of superficial bladder tumors. It aims to make the procedure safer and more precise.
HerlevAges 18 years+ - NCT06378242RecruitingPhase 1/Phase 2
Testing a bladder cancer drug for high-risk NMIBC patients
This trial tests a drug called Disitamab Vedotin, given directly into the bladder, for a type of early bladder cancer (high-risk NMIBC) that has a protein called HER2. It aims to see if this treatment can help avoid more radical surgery.
Guangzhou, GuangdongAges 18–75 - NCT07804056RecruitingPhase 3
Alpha1H before surgery for low-risk bladder cancer
This study tests a new medicine called Alpha1H that is given before the usual surgery to remove bladder cancer. It may help lower the risk of the cancer coming back.
PragueAges 18 years+ - NCT07728474Recruiting
Herbal supplement to prevent bladder cancer recurrence
This trial tests a herbal formula called LCS103 to see if it can help prevent bladder cancer from coming back after a tumor has been removed. It is for people with non-invasive bladder cancer that has been fully taken out by surgery.
HaifaAges 18 years+ - NCT07726992RecruitingPhase 3
New drug plus BCG for high-risk bladder cancer
This study tests a new immunotherapy drug (SHR-1501) combined with standard BCG therapy for people with a specific type of early bladder cancer (papillary-only, high-risk). The goal is to see if the combination helps prevent cancer from returning better than BCG alone.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07646145RecruitingPhase 2
Disitamab Vedotin Plus Mitomycin C for HER2-Positive Bladder Cancer
This trial tests a combination of two medications—disitamab vedotin (a targeted therapy) and mitomycin C (a chemotherapy)—for people with early-stage bladder cancer that has a specific protein called HER2. The goal is to prevent cancer from coming back after surgery in people who cannot or will not receive BCG treatment.
Taiyuan, ShanxiAges 18 years+ - NCT06108492RecruitingPhase 1
A new bladder cancer drug given directly into the bladder
This study tests a new drug, SHR-2005, given directly into the bladder through a catheter. It is for people with intermediate- or high-risk bladder cancer that hasn't spread into the muscle, and aims to see if it is safe and how well it works.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07514143Recruiting
Bladder Cancer Detection Study Using Urine Test
This study tests a new urine-based test called EpiCheck to help detect bladder cancer. You'll provide urine samples before or during a bladder procedure you're already scheduled to have, and researchers will see how well the test works.
San Diego, CaliforniaAges 22 years+
Hear when a new NMIBC trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for nmibc?
- Yes. Clin2 currently lists 44 recruiting nmibc studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a nmibc trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a nmibc trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.